Delicaflavone Reverses Cisplatin Resistance via Endoplasmic Reticulum Stress Signaling Pathway in Non-Small Cell Lung Cancer Cells
Received 31 March 2020
Accepted for publication 15 July 2020
Published 13 October 2020 Volume 2020:13 Pages 10315—10322
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Yao Dai
Xuewen Wang,1,* Bing Chen,1– 3,* Danfen Xu,1 Zhijun Li,4 Yuxia Sui,5,6 Xinhua Lin1– 3
1Department of Pharmaceutical Analysis, School of Pharmacy, Fujian Medical University, Fuzhou, Fujian, People’s Republic of China; 2Nano Medical Technology Research Institute, Fujian Medical University, Fuzhou, Fujian, People’s Republic of China; 3Higher Educational Key Laboratory for Nano Biomedical Technology of Fujian Province, Fujian Medical University, Fuzhou, Fujian, People’s Republic of China; 4School of Pharmacy, Fujian Medical University, Fuzhou 350180, Fujian, People’s Republic of China; 5Department of Pharmacy, Shengli Clinical Medical College of Fujian Medical University, Fuzhou 350001, People’s Republic of China; 6Department of Pharmacy, Fujian Provincial Hospital, Fuzhou 350001, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Xinhua Lin
Department of Pharmaceutical Analysis, Fujian Medical University, No. 1 Xueyuan Road, University Town, Fuzhou 350122, People’s Republic of China
Tel/Fax +86 13906909638
Email [email protected]
Department of Pharmacy, Fujian Provincial Hospital, No. 134 Dong Street, Fuzhou 350001, People’s Republic of China
Tel/Fax +86 15959090652
Email [email protected]
Background: The incidence and mortality of lung cancer continue to increase around the world; in 2018, new lung cancer cases accounted for 11.6% of all cancer cases, and lung cancer deaths accounted for 18.4% of cancer deaths. Cisplatin (DDP) is a first-line chemotherapy drug for lung cancer; however, DDP resistance can lead to a poor prognosis in patients with lung cancer. Therefore, reversing DDP resistance is a treatment goal.
Materials and Methods: Cell counting kit-8 (CCK8) assays, wound healing analyses, Transwell assays, in vitro tumor xenografts, and flow cytometry were used to detect the proliferation, migration, invasion, and apoptosis of multidrug resistant A549/DDP and PC9/DDP cells, respectively. Western blot was performed to detect protein levels of cleaved caspase-3, CHOP, and GRP78.
Results: Delicaflavone inhibited DDP resistance of lung cancer cells and decreased proliferation in a dose- and time-dependent manner. It also decreased migration and invasion and enhanced apoptosis. Western blots showed that delicaflavone overcame DDP resistance by increasing the expression of GRP78 and CHOP and the apoptosis-related protein cleaved caspase-3.
Conclusion: Delicaflavone can reverse DDP resistance in A549/DDP and PC9/DDP cells by inhibiting cell proliferation and migration and enhancing apoptosis and cleaved caspase-3 levels by increasing the expression of CHOP and GRP78 protein via the endoplasmic reticular stress pathway. It could be a useful therapeutic adjunct to treat DDP-resistant lung cancer.
Keywords: delicaflavone, Cisplatin; DDP, lung cancer, endoplasmic reticulum stress
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]